Pancreatic Cancer — Research Intelligence Dashboard
Prototype dashboard for architecture validation. Metrics shown are illustrative until registry enrichment and GRMI calculation engine are live.
Executive Summary
Data snapshot: February 2026
332
Total Active Trials
ClinicalTrials.gov Registry Subset
127
New Trials
Rolling 12 Months
26.8%
Phase I Density
Percentage
18
Distinct Biomarkers
Active
Accelerating
Research Momentum Classification (Rolling 12-Month Model)
Global Research Momentum Index (GRMI)
76
GRMI ScoreComposite index weighted as:
• Trial Velocity (30%)
• Early-Phase Density (25%)
• Biomarker Diversity (20%)
• Modality Expansion (15%)
• Geographic Spread (10%)
• Trial Velocity (30%)
• Early-Phase Density (25%)
• Biomarker Diversity (20%)
• Modality Expansion (15%)
• Geographic Spread (10%)
Accelerating
12-Month Trend
Component Breakdown
84
Trial Velocity Score
91
Early Phase Density
61
Biomarker Diversity
73
Modality Expansion
68
Geographic Spread
Phase & Modality Distribution
Phase Distribution
Modality Distribution
Geographic Spread
34
Countries Active
176
United States
Active Trials
98
Europe
Active Trials
58
Asia-Pacific
Active Trials
12-Month Geographic Expansion:+6 new countries, +42 new trial sites
Centers Actively Studying This Area
Institutions listed based on active pancreatic cancer trial count ≥ 25 (ClinicalTrials.gov registry analysis).
| Institution Name | Active Trials | Phase I % | Dominant Modality | Distinct Biomarkers |
|---|---|---|---|---|
| MD Anderson Cancer Center | 38 | 42% | Combination | 14 |
| Johns Hopkins Hospital | 34 | 38% | KRAS-targeted | 12 |
| Memorial Sloan Kettering Cancer Center | 31 | 35% | Immunotherapy | 11 |
| University of Pennsylvania | 27 | 44% | KRAS-targeted | 13 |
| Dana-Farber Cancer Institute | 29 | 31% | Combination | 10 |
| Mayo Clinic | 26 | 33% | Targeted Therapy | 9 |
Institutional Research Footprint Overlay
Institutional Overlay (Phase II Modeling)
This section will display global baseline vs. selected institution metrics side-by-side, enabling comparative analysis of institutional research positioning.
What This Signals
KRAS-targeted activity accelerating
KRAS G12C and G12D-targeted trials increased 142% year-over-year following validation
Early-phase density highest among flagship models
Phase I density at 26.8%, reflecting high innovation concentration and unmet clinical need
Combination strategy dominance
118 combination trials active, testing multi-agent approaches given historical monotherapy limitations
Immunotherapy subset expansion emerging
Immunotherapy trials in MSI-high and dMMR subsets increased, though overall response remains limited